Pre-Scribed cover art

Pre-Scribed

Pre-Scribed

By: Dr Nathan Goodyear
Listen for free

About this listen

 Welcome to *Pre-Scribed*, the official podcast of Dr. Nathan Goodyear, MD, MD(H) at Williams Cancer Institute. As an innovator in integrative oncology, Dr. Goodyear combines traditional medicine with holistic approaches to provide comprehensive cancer care. Join us as we delve into the latest advancements in integrative oncology, exploring ground breaking treatments and offering insights to inspire hope and healing. Each episode features expert interviews, patient stories, and practical advice aimed at empowering you to take charge of your health. Whether you’re a medical professional, a patient, or someone interested in the future of cancer treatment, *Pre-Scribed* offers valuable perspectives on the intersection of science and holistic care. Tune in to learn, heal, and discover the legacy of trust, truth, and service that defines Dr. Goodyear’s approach to medicine. Hope. Heal. Teach. Serve. Truth. Trust. Legacy. Subscribe now and join our community dedicated to innovative cancer care.Copyright 2024 All rights reserved. Alternative & Complementary Medicine Hygiene & Healthy Living Physical Illness & Disease
Episodes
  • Can Some Repurposed Drugs Undermine Immunotherapy? The Data Says Yes

    Can Some Repurposed Drugs Undermine Immunotherapy? The Data Says Yes
    Feb 6 2026

    📬 Join Dr. Goodyear’s Newsletter

    ➡️ https://pre-scribed.com/subscribe/

    Episode Overview

    In this solo episode, Dr. Nathan Goodyear, integrative oncology physician and founder of the Williams Cancer Institute, breaks down one of the most misunderstood topics in repurposed cancer therapeutics: which antiparasitic agents actually support immunotherapy—and which may undermine it. Using the framework of “cold” versus “hot” tumors, Dr. Goodyear examines ivermectin, albendazole, mebendazole, flubendazole, and fenbendazole through mechanisms of action, preclinical evidence, early human data, and real-world safety signals. The most provocative insight: some widely promoted agents may increase PD-L1 expression or liver toxicity, potentially interfering with immune checkpoint inhibitors, while others show credible immune-priming biology worth further investigation. This isn’t just a conversation—it’s a call to action to use repurposed medications responsibly, guided by evidence rather than hype.

    📌 Key Takeaways

    Cold tumors evade immune detection; “heating” the tumor microenvironment is essential for immunotherapy success “Inside-you vaccination” reframes intratumoral immune priming as real-time, personalized inoculation Ivermectin shows the strongest immune-checkpoint–relevant evidence, including preclinical synergy and early human trials Mechanistic data link ivermectin to immunogenic cell death and CD8+ T-cell infiltration Albendazole demonstrates PD-L1 degradation and checkpoint potentiation in preclinical melanoma models Mebendazole supports immune-adjacent myeloid reprogramming (M2 → M1), not proven cold-to-hot conversion Flubendazole suppresses PD-1 signaling in mice but lacks human data or direct ICI combination trials Fenbendazole shows no immune-heating benefit and carries reproducible hepatotoxicity risk Liver toxicity can confound or worsen immune-checkpoint hepatitis during treatment There is no “magic bullet” in oncology—effective care requires rational, evidence-based combinations Clinician-patient trust is rebuilt through engagement, transparency, and science-guided decision-making

    ⏱️ Timestamps

    0:00 – Cold tumors and immune priming

    1:14 – Repurposed antiparasitics in oncology

    3:25 – Why oversimplification fails cancer care

    5:26 – Ranking ivermectin, albendazole, and others

    7:00 – Ivermectin: cold-to-hot conversion biology

    9:10 – Personalized immune inoculation explained

    11:23 – Effector vs regulatory T-cell balance

    13:18 – Human trial signals and ASCO data

    17:04 – Mebendazole and myeloid immune shifts

    22:30 – Fenbendazole toxicity and PD-L1 concerns

    31:11 – Albendazole and checkpoint potentiation

    44:45 – Evidence hierarchy and safety synthesis

    🔔 Subscribe CTA

    🔔 Subscribe for more evidence-based conversations on the future of functional medicine.

    📚 Resources & Links

    ▶️ Watch more episodes + full show notes: https://prescribedpodcast.com

    📚 Learn more about integrative oncology: https://pre-scribed.com

    📞 Schedule a consultation or learn more: https://williamscancerinstitute.com

    Clinic & Socials

    🏥 Visit Dr. Goodyear’s clinic: https://www.drgoodyear.com

    📸 Follow us on Socials: https://linktr.ee/doctornathangoodyear
    Show More Show Less
    56 mins
  • The Gut Microbiome Is the Seed of Disease (And the Key to Healing) | FMT Breakthrough

    The Gut Microbiome Is the Seed of Disease (And the Key to Healing) | FMT Breakthrough
    Jan 23 2026

    📬 Join Dr. Goodyear’s Newsletter

    ➡️ https://pre-scribed.com/subscribe/

    Episode Overview

    In this episode of the Prescribed Podcast, Dr. Nathan Goodyear sits down with Jason Klop, N.D. (CEO & Founder, Novel Biome) and Shaina Cahill, Ph.D. (Director of Operations & Medical Affairs) to explore the gut microbiome as a powerful “seeding event” for both disease and healing. They break down how modern medicine has often prioritized “pharming disease” over “farming health,” and why fecal microbiota transplantation (FMT) is emerging as a serious clinical tool to restore microbial ecology, support immune function, and potentially enhance outcomes in cancer care and beyond. From the gut–brain axis to early-life microbial programming, this isn’t just a conversation—it’s a call to action.

    📌 Key Takeaways

    The gut microbiome can “seed” disease or become the foundation for reprogramming health Why dysbiosis may drive inflammation, immune imbalance, and chronic illness How FMT is evolving from fringe to a structured clinical + research pathway Donor screening, manufacturing quality, and delivery methods matter The gut–brain connection and why neurologic symptoms may start in the gut Why ultra-processed foods and antibiotics can shift microbial ecosystems long-term How microbiome disruption may affect cancer therapy tolerance and recovery The potential role of FMT as an adjunct to immunotherapy in select contexts Why prevention starts with “seeding events” like birth, feeding, and environment Post-treatment microbiome restoration may be critical for long-term resilience

    ⏱️ Timestamps

    0:00 - Why the gut is the “seed” of disease and healing

    1:31 - Episode intro + Seed to Soil framework

    3:10 - Meet Jason Klop, N.D. (Novel Biome)

    5:30 - Meet Shaina Cahill, Ph.D. (Gut–brain science)

    6:56 - The origin story of Novel Biome

    12:35 - Why the gut impacts brain aging + development

    16:45 - Parkinson’s early GI warning signs

    20:20 - The problem with compartmentalized medicine

    28:10 - Microbiome milestones + aging parallels

    33:40 - Inherited dysbiosis: antibiotics, C-sections, environment

    41:25 - Prevention: re-seeding health early

    47:05 - Cancer care + microbiome disruption during treatment

    55:55 - Metastasis, leaky barriers, and the immune system

    🔔 Subscribe for more evidence-based conversations on the future of functional medicine.

    📚 Resources & Links

    ▶️ Watch more episodes + full show notes: https://prescribedpodcast.com

    🧬 Novel Biome: https://www.novelbiome.com

    📚 Learn more about integrative oncology: https://pre-scribed.com

    📞 Schedule a consultation or learn more: https://williamscancerinstitute.com

    Citations (APA):

    Kim, Y., et al. (2024). Cell Host & Microbe. https://doi.org/10.1016/j.chom.2024.06.010 Li, R., et al. (2025). Journal of Hepatology. https://doi.org/10.1016/j.jhep.2025.10.008 Massara, M., et al. (2025). iScience. https://doi.org/10.1016/j.isci.2025.111874

    Clinic & Socials Links

    🏥 Visit Dr. Goodyear’s clinic: https://www.drgoodyear.com 📸 Follow us on Socials: https://linktr.ee/doctornathangoodyear
    Show More Show Less
    1 hr and 7 mins
  • Cancer Isn’t What You Think: The New Science of Tumor Microenvironments with Dr. Anderson

    Cancer Isn’t What You Think: The New Science of Tumor Microenvironments with Dr. Anderson
    Dec 10 2025
    📬 Join Dr. Goodyear’s Newsletter ➡️ https://pre-scribed.com/subscribe/ Episode Overview In this episode of the Prescribed Podcast, Dr. Nathan Goodyear sits down with Dr. Paul Anderson, ND—an integrative oncologist, researcher, and educator whose work has reshaped how clinicians think about cancer stem cells, the tumor microenvironment, and complex chronic disease. Together, they unpack why standard therapies like chemotherapy, radiation, and surgery can win a short-term battle by shrinking visible tumors while silently empowering cancer stem cells and setting the stage for relapse. They explore how an inflamed tumor microenvironment, immune dysregulation, environmental toxicity, and a disrupted microbiome can hijack normal defenses and turn them into cancer’s allies. From pediatric and early-onset cancers to aggressive recurrences and the legacy of his Advanced Applications in Medical Practice (AAMP) conferences, Dr. Anderson argues that medicine must move beyond silos, embrace collaboration, and return to its roots as a teaching profession that multiplies healing. This isn’t just a conversation—it’s a call to action for patients and clinicians to understand the biology beneath treatment and help build the bridges that will shape the future of integrative oncology. Listeners will leave with clearer next steps. 📌 Key Takeaways Cancer stem cells and daughter cells respond very differently to treatment. Conventional therapies can debulk large tumors while enriching a deeper stem-cell pool that drives relapse. The tumor microenvironment is the real chessboard. Immune cells, stromal cells, cytokines, and signaling molecules form a “field of play” that can tilt toward either tumor control or tumor promotion. Short-term victories can create long-term biological debt. Surgery, chemo, and radiation may be necessary to reduce tumor burden, but without changing the microenvironment, residual stem cells can fuel more aggressive, treatment-resistant disease. Plasticity means cancer can adapt quickly. Under the wrong signals, daughter cancer cells—and even previously normal cells—can acquire stem-like traits and become engines of progression. Cancer today is not the cancer of yesterday. Over his clinical career, Dr. Anderson has seen more pediatric cancers, more early-onset malignancies, and more aggressive second primaries emerging after initial remission. Patients are driving the demand for integrative oncology. People want both remission and quality of life, pressing oncologists and integrative practitioners to collaborate instead of compete. Chronic illness and cancer share common terrain. Toxic burden, immune dysregulation, and environmental stressors show up both in complex chronic illness and oncology. Bridge-building is the real legacy. Stories of initially skeptical oncologists who become collaborative partners highlight how data, safety, and patient outcomes can open minds and unify the field around what helps patients most. ⏱️ Timestamps 0:00 – Opening quote: chemo, radiation, and cancer stem cells 1:20 – Welcome to Prescribed: where integrative oncology meets holistic healing 2:23 – Introducing Dr. Paul Anderson: scientist, healer, teacher, bridge-builder 4:03 – From lab work and family practice to naturopathic oncology and AAMP 7:40 – Why teaching clinicians may help more patients than any single practice 11:27 – Is cancer “just low T-cells and NK cells”? The complexity of tumor immunology 13:22 – Drawing the tumor microenvironment “chessboard” and its key players 18:14 – How chemo and radiation debulk tumors but can strengthen cancer stem cells 22:25 – Plasticity, reprogramming, and how environment shapes stem-like behavior 28:12 – Three decades of oncology: pediatric and early-onset cancers on the rise 32:33 – Recurrences that look nothing like the original tumor—and why that matters 36:31 – Patients as the first agents of change in integrative cancer care 42:17 – Chronic illness, toxic load, and shared immune terrain with cancer 45:11 – Microbiome, environment, and “farming disease” versus farming health 48:36 – Can you really teach well if you’re not still practicing? 🔔 Subscribe CTA 🔔 Subscribe for more evidence-based conversations on the future of functional medicine. 📚 Resources & Links ▶️ Watch more episodes + full show notes: https://prescribedpodcast.com 🧬 Dr. Paul Anderson’s Website & Teaching Hub: https://draonline.com 📚 Learn more about integrative oncology: https://pre-scribed.com 📞 Schedule a consultation or learn more: https://williamscancerinstitute.com Clinic & Socials Links 🏥 Visit Dr. Goodyear’s clinic: https://www.drgoodyear.com 📸 Follow us on Socials: https://linktr.ee/doctornathangoodyear
    Show More Show Less
    59 mins
No reviews yet